Moderna Shares Tumble 0.49% on $250M Volume, Rank 422nd in Trading Activity

On September 26, 2025, Moderna (MRNA) closed with a 0.49% decline, trading a volume of $250 million, ranking 422nd in terms of trading activity on the day. The biotech giant's shares faced downward pressure amid mixed market sentiment and evolving sector dynamics.

Recent developments highlighted Moderna's strategic focus on expanding its mRNA platform beyond vaccines. A partnership update with a European research consortium underscored progress in oncology trials, though the timeline for commercialization remains uncertain. Additionally, regulatory scrutiny over clinical trial disclosures added short-term volatility, as investors weighed long-term pipeline potential against near-term execution risks.

Analysts noted that Moderna's valuation continues to hinge on its ability to diversify revenue streams beyond the pandemic-era demand for its COVID-19 vaccine. While preclinical data for a novel infectious disease candidate showed promise, the lack of near-term catalysts—such as Phase III approvals—left the stock vulnerable to broader market rotations into defensive assets.

To run this back-test accurately, I first need to pin down a couple of practical details and confirm the scope so I can prepare the correct data-retrieval plan: 1. Universe • Do you want to cover all U.S. listed common stocks (NYSE + Nasdaq) or a specific subset such as the S&P 1500, Russell 3000, etc.? • Should we exclude penny stocks, ADRs, ETFs and preferreds? 2. “Daily trading volume” metric • Rank by share volume (shares traded) or by dollar volume (shares × price)? • Rank date: use yesterday’s volume to decide today’s trade list (i.e., form the portfolio at today’s open) – is that acceptable? 3. Trade mechanics • Entry: buy the selected stocks at the day’s open. • Exit: sell them at the same day’s close (holding period ≈ one trading day). • Equal-weight each position? (Default is equal-weight.) • Rebalance every trading day (i.e., replace the entire list each day)? 4. Transaction frictions • Ignore commissions/slippage for this first pass, or do you want to layer in a roundtrip cost assumption (e.g., 2 bp each side)? 5. Output format • Aggregate portfolio equity curve and summary statistics (CAGR, annualized vol, max drawdown, Sharpe), plus key daily return series. Once these are confirmed, I can generate the data-retrieval plan, pull the daily volumes/prices, build a daily signal file, and run the back-test. Let me know, and we’ll proceed.